Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JCXH-211 |
| Synonyms | |
| Therapy Description |
JCXH-211 consists of a self-replicating RNA (srRNA) for IL-12 contained within a lipid nanoparticle, which potentially results in enhanced antitumor immune response and induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JCXH-211 | JCXH 211|JCXH211 | JCXH-211 consists of a self-replicating RNA (srRNA) for IL-12 contained within a lipid nanoparticle, which potentially results in enhanced antitumor immune response and induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05539157 | Phase I | JCXH-211 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | Unknown status | USA | 0 |